ValiPharma

Cronos Therapeutics, Ltd., a biopharmaceutical company, develops therapeutics and diagnostics based on epigenomics for the detection and

Cronos Therapeutics, Ltd., a biopharmaceutical company, develops therapeutics and diagnostics based on epigenomics for the detection and treatment of cancer. Its GeneICE compounds represent a way of treating diseases by acting to shut down harmful genes and therefore prevent their expression. The company's HyperGenomics platform characterizes disease state by detecting areas on the chromosome where genes are active. Its compound, which is undergoing development, acts to shut down the Bcl-2 gene. Cronos Therapeutics, Ltd. was founded in 2004 and is based in London, the United Kingdom. As of October 3, 2006, Cronos Therapeutics Ltd. is a subsidiary of ValiRX PLC.